Drug updated on 9/4/2024
Dosage Form | Nasal spray (intranasal; 10 mg) |
Drug Class | Calcitonin gene-related peptide receptor antagonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the acute treatment of migraine with or without aura in adults.
Latest News
Summary
- Zavzpret (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- Zavegepant is effective in providing pain relief within 2 hours and sustained pain relief over 24 hours but is less effective compared to lasmiditan (100 mg, 200 mg), rimegepant (75 mg), and zolmitriptan (5 mg).
- Zavegepant shows a trend towards reduced pain relapse between 2 to 48 hours, but the difference was not statistically significant. It is also less effective in achieving freedom from nausea, phonophobia, and photophobia compared to DFN-02 and ROX-828.
- Zavegepant demonstrates significant improvement in freedom from most bothersome symptoms (MBS) at 2 hours. However, in comparative effectiveness, zolmitriptan (5 mg) and rimegepant (75 mg) are more effective in other measured outcomes.
- Zavegepant demonstrated the lowest risk of adverse events (AEs) among intranasal agents studied (OR: 2.04, 95% CI: 1.37 to 3.03), while dihydroergotamine nasal spray had the highest risk (OR: 9.65, 95% CI: 4.39 to 21.22).
- Lasmiditan was associated with a high incidence of adverse effects, including dizziness, somnolence, asthenia, paresthesia, and fatigue.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Zavzpret (zavegepant) Prescribing Information. | 2023 | Pfizer Laboratories, Div Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. | 2024 | The Journal of Headache and Pain |
Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. | 2023 | The Journal of Headache and Pain |
Safety and efficacy of zavegepant in treating migraine: a systematic review. | 2023 | Cureus |
Zavegepant nasal spray for the acute treatment of migraine: a meta analysis. | 2023 | Medicine |